Category: Analysis - Page 9 - Psychedelic Alpha

Issue 2 of The Psychedelic Practitioner is out now.

Read more about the article Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of Staff

Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of Staff

Post published:October 31, 2024
Post category:Analysis News Pα+

Read more about the article Final Stretch for Question 4: Controversy, Advocacy, and Celebrity Voices Shape Psychedelic Vote

Final Stretch for Question 4: Controversy, Advocacy, and Celebrity Voices Shape Psychedelic Vote

Post published:October 28, 2024
Post category:Analysis News

Read more about the article Psychedelics Take Centre Stage in Massachusetts’ Local Media

Psychedelics Take Centre Stage in Massachusetts’ Local Media

Post published:October 21, 2024
Post category:Analysis News

Read more about the article Massachusetts Psychiatrists Push Back on Psychedelic Reform as Ballot Vote Looms: An Interview with Nassir Ghaemi

Massachusetts Psychiatrists Push Back on Psychedelic Reform as Ballot Vote Looms: An Interview with Nassir Ghaemi

Post published:October 10, 2024
Post category:Analysis News

Read more about the article Psychedelic Funding Update: Q3 2024

Psychedelic Funding Update: Q3 2024

Post published:October 8, 2024
Post category:Analysis Pα+

Read more about the article The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits

The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits

Post published:September 30, 2024
Post category:Analysis News Pα+

Read more about the article Real-World Data Reveals Variability in Access to, and Use of, Spravato

Real-World Data Reveals Variability in Access to, and Use of, Spravato

Post published:September 13, 2024
Post category:Analysis News Pα+

Read more about the article What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2)

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2)

Post published:August 28, 2024
Post category:Analysis News Pα+

Read more about the article What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 1)

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 1)

Post published:August 22, 2024
Post category:Analysis News Pα+

Read more about the article Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran, Doblin Resigns Board

Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran, Doblin Resigns Board

Post published:August 15, 2024
Post category:Analysis News Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.